Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome
- PMID: 2875864
- DOI: 10.2165/00003495-198632030-00001
Famotidine. Pharmacodynamic and pharmacokinetic properties and a preliminary review of its therapeutic use in peptic ulcer disease and Zollinger-Ellison syndrome
Abstract
Famotidine is a new histamine H2-receptor antagonist. On a weight basis, famotidine is 20 times more potent than cimetidine and 7.5 times more potent than ranitidine in inhibiting basal and pentagastrin-stimulated gastric acid secretion in humans. Therapeutic trials have shown that famotidine 20 mg twice daily or 40 mg at bedtime may be an effective alternative to standard doses of cimetidine for healing gastric ulcers and to standard doses of cimetidine and ranitidine for healing duodenal ulcers. When used prophylactically, a single 20 mg dose of famotidine at night decreases the incidence of duodenal ulcer recurrence (versus placebo). However, further study is needed to clarify the comparative efficacy of the H2-receptor antagonists, in particular as maintenance therapy for healed peptic ulcer. Preliminary results in a few patients with Zollinger-Ellison syndrome indicate that famotidine, alone or in combination with an anticholinergic agent, gives good control of gastric acid hyperacidity with no evidence of biochemical or haematological toxicity. Famotidine appears to be well tolerated. Unlike cimetidine, it does not have antiandrogenic effects or alter hepatic metabolism of drugs. However, wider clinical experience with famotidine is needed to accurately determine its relative tolerability compared with other anti-ulcer drugs. Thus, famotidine appears to be a suitable and well tolerated alternative to cimetidine and ranitidine for healing peptic ulcers, but wider clinical experience is needed to assess its relative efficacy and tolerability in the long term maintenance treatment of patients with healed ulcers as well as in patients with Zollinger-Ellison syndrome.
Similar articles
-
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. Drugs. 1989. PMID: 2573505 Review.
-
Comparison of famotidine with cimetidine and ranitidine.Clin Pharm. 1988 Apr;7(4):271-84. Clin Pharm. 1988. PMID: 2896559 Review.
-
Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.Drugs. 1982 Oct;24(4):267-303. doi: 10.2165/00003495-198224040-00002. Drugs. 1982. PMID: 6128216 Review.
-
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Jul;32(1):15-47. doi: 10.2165/00003495-198632010-00002. Drugs. 1986. PMID: 3527658 Review.
-
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.Am J Gastroenterol. 1987 Jun;82(6):504-6. Am J Gastroenterol. 1987. PMID: 2883885
Cited by
-
A comparison of roxatidine acetate 150 mg once daily and 75 mg twice daily in gastric ulcer healing.Drugs. 1988;35 Suppl 3:127-33. doi: 10.2165/00003495-198800353-00022. Drugs. 1988. PMID: 2905241 Clinical Trial.
-
Pharmacokinetics of newer drugs in patients with renal impairment (Part I).Clin Pharmacokinet. 1991 Apr;20(4):293-310. doi: 10.2165/00003088-199120040-00004. Clin Pharmacokinet. 1991. PMID: 2036748 Review.
-
Guide to drug dosage in renal failure.Clin Pharmacokinet. 1988 Nov;15(5):326-54. doi: 10.2165/00003088-198815050-00005. Clin Pharmacokinet. 1988. PMID: 3060292 Review. No abstract available.
-
Therapeutic Potential of Targeting ß-Arrestin.Front Pharmacol. 2019 Mar 6;10:124. doi: 10.3389/fphar.2019.00124. eCollection 2019. Front Pharmacol. 2019. PMID: 30894814 Free PMC article. Review.
-
Haematological adverse effects of histamine H2-receptor antagonists.Med Toxicol Adverse Drug Exp. 1988 Nov-Dec;3(6):430-48. doi: 10.1007/BF03259895. Med Toxicol Adverse Drug Exp. 1988. PMID: 2905759 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical